Background-Kinins are modulators of cardiovascular function. After ischemic injury, enhanced kinin generation may contribute in processes responsible for tissue healing. Methods and Results-Using pharmacological and genetic approaches, we investigated the role of kinin B 1 receptor in reparative angiogenesis in a murine model of limb ischemia. The effect of B 1 pharmacological manipulation on human endothelial cell proliferation and apoptosis was also studied in vitro. Abrogation of B 1 signaling dramatically inhibited the native angiogenic response to ischemia, severely compromising blood perfusion recovery. Outcome was especially impaired in B 1 knockouts that showed a very high incidence of limb necrosis, eventually leading to spontaneous auto-amputation. Conversely, local delivery of a long-acting B 1 receptor agonist enhanced collateral vascular growth in ischemic skeletal muscle, accelerated the rate of perfusion recovery, and improved limb salvage. In vitro, B 1 activation stimulated endothelial cell proliferation and survival, whereas B 1 antagonism induced apoptosis. Conclusions-Our results indicate that the B 1 plays an essential role in the host defense response to ischemic injury. B 1 signaling potentiation might be envisaged as a utilitarian target for the treatment of ischemic vascular disease.
I schemic disease represents a major health problem and is expected to become the new worldwide epidemic of the third millennium. After occurrence of vascular occlusion, clinical outcome mainly depends on the native potential to develop new collaterals, a defense response aimed to maintain tissue perfusion and function. However, under certain conditions such as diabetes, hypercholesterolemia, and hypertension, post-ischemic healing is compromised because of a defective modulation of angiogenic growth factors. [1] [2] [3] Thus, supplementation with angiogenic substances has been proposed as a possible mechanism to overcome the failure in mounting an adequate vascular response. 4, 5 The kallikrein-kinin system (KKS), long regarded as a modulator of cardiovascular homeostasis, nociception, and inflammation, 6, 7 is now being considered for its potential in reparative and therapeutic angiogenesis. 3, 8, 9 Kinin peptides cleaved from kininogens by kallikreins interact with G protein-coupled B 1 and B 2 receptors (B 1 and B 2 ), thus leading vascular endothelial cells (ECs) to release autacoids such as nitric oxide (NO) and prostaglandins. 10, 11 The constitutive B 2 is responsible for the majority of biological effects of bradykinin (BK) and Lys-BK. In contrast, the B 1 preferentially binds desArg 9 -BK and Lys-desArg 10 -BK, is induced by tissue damage via activation of transcription factor nuclear factor B, and does not desensitize after exposure to ligand. [12] [13] [14] Circumstantial evidence for a role of B 1 in reparative angiogenesis comes from the observation that B 1 gene expression is up-regulated by ischemia in skeletal muscle or myocardium. 8, 15 In vitro, kinins promote EC proliferation via activation of the B 1 -cAMP pathway. 16, 17 In vivo, B 1 stimulation induces neovascularization in the rabbit cornea 17 and is responsible for capillary proliferation evoked by BK 18 or tissue kallikrein gene transfer. 8, 19 The aim of the present study was to firmly establish the functional relevance of B 1 in post-ischemic neovascularization. We demonstrated that B 1 signaling plays an essential role in reparative angiogenesis by modulating EC proliferation and survival. Moreover, potentiation of this mechanism exerts a therapeutic effect by accelerating spontaneous healing. Exploitation of the angiogenic potential of B 1 agonists may be envisaged for the treatment of patients with peripheral artery disease.
Methods
All procedures complied with the standards stated in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of Sciences, Bethesda, Md, 1996) . CD1 mice were purchased from Charles River, Comerio, Italy. B 1 knock outs 20 were provided by Max Delbrück Center for Molecular Medicine (Berlin-Buch, Germany), whereas their wildtype J129 controls were obtained from Jackson Laboratories (Bar Harbor, Me).
In Vivo Experimental Protocols
With mice under the effect of 2,2,2 tribromoethanol anesthesia (880 mmol/kg BW IP, Sigma-Aldrich), the left femoral artery was exposed, dissected free, and excised. 8 Three groups were studied: (1) CD1 mice were given the B 1 9 -BK (R715, at 50 nmol/kg BW per day, nϭ7), or vehicle (sterile saline, nϭ8), and were followed-up for 21 days from surgery. Drugs were delivered IP by osmotic mini-pumps (Alza Co., Palo Alto, CA). Selectivity of antagonists has been previously reported. 7 (2) The second group consisted of B 1 knockouts (nϭ15) and J129 controls. The latter were subdivided into 2 groups given DALBK (nϭ8) or saline (nϭ10) IP. Mice were euthanized 14 days from surgery. (3) CD1 and J129 mice had their left adductor muscles injected with B 1 agonist Sar[D-Phe 8 ]des-Arg 9 -BK (R916, at 2.5 mol/kg BW in 20 L saline once or twice a day, starting on the day of surgery, nϭ10 each dose per strain) or vehicle (nϭ10 each strain) and were followed-up for 14 days from ischemia.
Histological Assessment of Neovascularization
Capillary and myofiber densities of both adductors were determined at necroscopy. Anesthetized mice were perfused with PBS (1 minute) and then with 10% buffered formalin (10 minutes) at 100 mm Hg via the abdominal aorta. After paraffin embedding, 3 m-thick sections were cut from each sample with muscle fibers transversely oriented, and stained with hematoxylin and eosin.
Sections were analyzed in a blinded fashion using an ocular reticle (9604-m 2 area) at 1000ϫ magnification. Twenty-five fields were randomly counted and averaged. The number of capillary (n cap ) and myofiber (n fiber ) profiles per field was used to compute capillary or myofiber numerical density per square mm of muscle, according to the following formulas: n cap /mm 2 ϭ n cap in total fields/total field area and n fiber /mm 2 ϭ n fiber in total fields/total field area. In addition, capillary density was normalized to myofiber density (n cap /n fiber ). 3, 8 
Post-Ischemic Hemodynamic Recovery
Hindlimb blood flow of anesthetized mice was measured by laser Doppler flowmetry (Lisca, Sweden) under basal conditions and then weekly after surgery, and the ratio of perfusion between ischemic to non-ischemic foot was calculated. 8 
EC Proliferation and Apoptosis
Human umbilical vein ECs (HUVECs) were cultured in M199 supplemented with 20% fetal bovine serum (FBS, Gibco), 0.3% bovine brain extract (BBE, Clonetics), and antibiotics, and were maintained at 37°C in 5% CO 2 /95% air. Experiments were performed on cells at passages between 2 and 5.
The effect of B 1 stimulation on HUVEC proliferation was assayed after a total of 24 hours of serum starvation. In a set of experiments, the last 2 hours of starvation were combined with incubation in a modified Krebs buffer (137 mmol/L NaCl, 3.8 mmol/L KCl, 0.49 mmol/L MgCl 2 , 0.9 mmol/L CaCl 2 , and 4.0 mmol/L Hepes) supplemented with 10 mmol/L 2-deoxyglucose, 20 mmol/L sodium lactate, 1 mmol/L sodium dithionite, and 12 mmol/L KCl (pH 6.5) to evoke simulated ischemia (SI). 21 Then, ischemic or not ischemic HUVECs were incubated for 72 hours in M199 medium containing 1% FCS and added with the B 1 agonist R916 (50 nmol/L to 1 mol/L) or vehicle (PBS). In a separate experiment, R916 (100 nmol/L) was co-incubated with either R715 (1 mol/L) or PBS. Incubation was carried out in the presence of 1 Ci/mL [ 3 H] thymidine (specific activity 5 Ci/mmol, Amersham Pharmacia Biotech). The medium was then removed and the cell monolayer in each well was washed twice with PBS, exposed to 5% trichloroacetic acid (500 L) for 5 minutes, and fixed in methanol (500 L). Finally, cells were digested by adding 25 mol/L formic acid (500 L). Each digest was transferred to a scintillation vial and radioactivity was determined by a scintillation counter (LKB Instrument Inc). Experiments were repeated at least 6 times.
To assess the effect of B 1 blockade on apoptosis, HUVECs suspended in a normal culture medium were seeded in gelatinated 24-well dishes at a density of 4ϫ10 4 cells per well, and allowed to attach overnight. Fresh media supplemented with low (2%) or normal (20%) FBS and containing R916 (100 nmol/L to 5 mol/L), R715 (100 nmol/L to 5 mol/L), or PBS was then added for 24 or 48 hours. Experiments were performed at the standard atmosphere or under hypoxia obtained by placing cell plates in a modular incubator chamber (Billups-Rothenberg) filled with 5%CO 2 /95%N 2 . At the end of the incubation period, supernatant was collected for LDH determination by the Promega Cytotoxic Assay and apoptosis was investigated by 4Ј-6Ј-diaminidino phenylindole (DAPI) staining (Roche). To this aim, cells were fixed in 4% paraformaldehyde for 10 minutes, washed twice with PBS and incubated with DAPI (1 g/mL PBS) for 20 minutes. Wells were examined by fluorescent microscopy at 100ϫ magnifications. Three randomly selected fields per well were photographed with a videocamera and then analyzed for total cell number. Apoptotic HUVECs, identified by condensation and fragmentation of their nuclei, were counted by a researcher blinded to the treatment. In each examined field, the total cell number was also computed to calculate the percent of apoptotic cells. Each experiment was repeated 3 to 6 times.
Statistical Analysis
All results are expressed as meanϮSEM. Multivariate repeatedmeasures ANOVA was performed to test for interaction between time and grouping factor. In multiple comparisons among independent groups in which ANOVA and F test indicated significant differences, the statistical value was determined according to the Bonferroni's method. Differences within and between groups were determined using paired or unpaired Student's t test, respectively. The comparative incidence of limb salvage was evaluated by 2 analysis. A P value Ͻ0.05 was interpreted to denote statistical significance.
Results

Impact of B 1 Signaling on Microvascular Response to Ischemia
As depicted in Figure 1A , vehicle-treated J129 showed a 1.7-fold increase in adductor muscle capillarity 14 days from ischemia induction (950Ϯ158 versus 544Ϯ66 cap/mm 2 in contralateral normoperfused muscles, PϽ0.01). The reparative response was attenuated by DALBK (773Ϯ71 versus 603Ϯ92 cap/mm 2 in contralateral muscles, PϭNS) and absent in B 1 knockouts (367Ϯ59 versus 383Ϯ45 cap/mm 2 in contralateral muscles, PϭNS). Results did not differ when expressed as capillary to myofiber ratio ( Figure 1B) .
As shown in Figure 2 , the instrumental relevance of endogenous B 1 signaling was confirmed in the CD1 strain. In fact, although capillary density was increased by 1.9-fold 3 weeks from induction of ischemia in vehicle-treated animals (1008Ϯ137 versus 516Ϯ79 cap/mm 2 in contralateral adductors, PϽ0.001), this response was prevented by either DALBK or R715 (PϽ0.01 for both comparisons). Similar results were obtained after normalization of capillarity by fiber number (data not shown).
We then evaluated whether reparative neovascularization would be potentiated by R916 agonist local administration.
Because vascular effects of the 2 doses tested were superimposable, results were cumulated. As shown in Figure 3A , capillary density of ischemic adductors was enhanced in R916-treated CD1 (1207Ϯ46 versus 917Ϯ112 cap/mm 2 in vehicle group, PϽ0.005). Results were comparable when expressed as a capillary-to-myofiber ratio ( Figure 3B ). In contrast, capillarity of contralateral normoperfused noninjected muscles remained unaffected. Similar results were obtained in R916-treated J129, whereas, as expected, the agonist did not improve the deficient capillary response typical of B 1 knockouts (data not shown).
Effect of B 1 Manipulation on Post-Ischemic Perfusion Recovery
As depicted in Figure 4 , CD1 showed an impaired hemodynamic recovery under chronic B 1 blockade by either R715 or DALBK. In fact, although 3 weeks were enough for vehicletreated mice to recover, the limbs of antagonist-treated mice were still hypoperfused at the end of this time frame (PϽ0.01).
As shown in Figure 5 , recovery of mice with B 1 genetic disruption was dramatically compromised, due to the virtually absent neovascularization (see above). Limb necrosis developed in the majority of B 1 knockouts, leading to spontaneous auto-amputation in 13 out 15 animals (87 versus 29% in J129, PϽ0.01). The 2 remainders showed persistent limb ischemia at 2 weeks from surgery, with a blood perfusion to the ischemic limb 69 and 63% less than that of contralateral side. In consideration of the severe outcome, animals were sacrificed at this stage to avoid unnecessary pain.
Conversely, local injection of the B 1 agonist R916 into the ischemic muscles of J129 improved clinical outcome (PϽ0.001). Limb salvage occurred within 2 weeks in 12 (60%) out 20 mice. Among remainders, 3 (15%) showed residual ischemia and 5 (25%) experienced foot necrosis. As shown in Figure 6 , sequential analysis of limb blood flow denoted an accelerated recovery in R916-treated groups. With the highest dose, a beneficial effect was already detected at 1 week.
Effect of B 1 Signaling on EC Proliferation and Survival
Pharmacological manipulation of the B 1 affects HUVEC proliferation and apoptosis. After SI preconditioning, HUVEC spontaneous mitotic activity was higher (data not shown, PϽ0.05) and the response to R916 increased (2.1-fold versus 1.5-fold in not SI in response to 100 nmol/L R916, PϽ0.05), suggesting that the B 1 receptor might be upregulated by SI. Figure 7 shows the dose-response to R916 after SI. The proliferative effect of R916 was prevented by R715 (Figure 7) , whereas R715 per se was ineffective (data not shown).
In experiments performed at low serum concentration, R916 reduced apoptosis ( Figure 8A and 8B), whereas R715 had no effect (data not shown). On the other hand, R715 increased apoptosis of HUVECs cultured under standard FBS concentration ( Figure 8C and 8D) , suggesting that B 1 ligands generated by ECs from serum-derived substrates may act autocrinally to favor cell survival. 22 LDH levels did not differ among groups (data not shown), excluding a cytotoxic effect of R715. No differences were seen when cells were incubated under hypoxic conditions (data not shown).
Discussion
Circumstantial evidence derived from pharmacological studies suggests a role for the B 1 receptor in capillary proliferation. 8,16 -19 By exploiting the powerful tool of gene knockout strategy, we demonstrate that the endogenous B 1 signaling is indeed essential for developing new blood vessels with functional relevance for limb post-ischemic recovery. Another important finding of the present study is the discovery that B 1 stimulation by local administration of a specific receptor agonist has a potential in therapeutic angiogenesis.
Increased kinin levels in the coronary sinus blood of dogs and humans have been reported after myocardial ischemia. 23, 24 For a long time, the compensatory relevance of this phenomenon has been attributed to the ability of kinins to cause vasodilation and preserve muscular energy content. 25, 26, 27 More recently, the theory has been proposed that kinins may exert long-term protection on ischemic tissue by potentiation of neovascularization. We and others have documented that B 1 gene expression is activated in ischemic skeletal muscles and myocardium. 8, 15 Furthermore, in vitro studies showed that engagement of kinin B 1 by des-Arg 10 -kallidin or R916 stimulates proliferation of coronary ECs. 16, 17 We found that the mild proliferative effect of R916 on HUVECs under normal conditions is potentiated by preconditioning with a culture system mimicking an ischemic milieu. This finding favors possible implication of the B 1 in the EC program leading to capillarization in response to an ischemic injury. Furthermore, we demonstrated that the B 1 plays a role in EC survival.
Seminal studies from our group showed that B 1 pharmacological blockade inhibits capillary proliferation in response to limb ischemia. 8 This assumption was confirmed by the use of 2 different antagonists and replicated in both wild-type J129 and CD1 strains. Moreover, we provided the new information that B 1 antagonism severely impairs blood perfusion recovery of ischemic muscles. Another major novelty of the present study is the observation that genetic disruption of the B 1 results in the absolute failure to mount reparative angiogenesis. The vascular deficit led to an unusual incidence of limb necrosis and auto-amputation. Congenital absence of the receptor could account for the severe outcome of B 1 knockouts compared with that of antagonist-treated animals. Moreover, the mild reduction in capillarity that was evidenced in not ischemic limbs of knockouts calls for further studies aimed to assess a potential role of B 1 in vasculogenesis.
Besides acting as direct modulators of EC growth and survival, kinins may participate in post-ischemic neovascu- larization by increasing extravasation of plasma proteins that would provide a provisional scaffold for growing vasculature. Furthermore, kinins are potent attractants for leukocytes, which represent an additional source of EC growth factors, as well as kallikrein and kininogen, ie, the components required for kinin generation. 6, 28 Interestingly enough, B 1 knockouts feature a drastic reduction in the extravasation of leukocytes in inflamed tissues, 20 a deficit that may eventually contribute in impaired neovascularization.
Another intriguing possibility regards coupling of B 1 receptor to neuronal modulation of angiogenesis, as supported by the observation that kinin challenge stimulates nonadrenergic non-cholinergic C-fibers to release the proangiogenic tachykinin neuropeptides. 29 Accordingly, the alteration in C-fiber trafficking that has been reported in B 1 knockouts 20 may contribute in impaired neovascularization.
The present study clearly indicates that ligands activating the B 1 possess a significant therapeutic potential for the treatment of peripheral ischemia. Interestingly, R916 also increases capillarity of normoperfused muscle (Costanza Emanueli, unpublished results, 2001), suggesting a potential application in patients experiencing intermittent ischemia. Administration of B 1 agonists could be safer than adenovirusmediated growth factor gene delivery that reportedly produces harmful side effects mainly attributed to viral vectors. Furthermore, receptor agonists are devoid of immunogenic activity. This fact represents another important advantage over adenovirus-mediated gene therapy, whose immunogenicity precludes long-term duration of transgene expression as well as effectiveness in case of readministration.
It could be argued that uncontrolled B 1 activation might trigger local or systemic inflammatory reactions in susceptible individuals. However, such a strategy is made less risky by the availability of potent receptor antagonists. Further- 
